Loxo Oncology, Inc. $LLY
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS7
PHASE 3 / 2-36
RECRUITING2
READOUTS ≤12 MONTHS2
READOUT SLIPPED >6 MO43%
Delay Index: of 7 active trials registered more than a year ago, 3 have moved their primary completion (readout) date by more than 6 months since first registration (median +3.1 months). See all sponsors →
Open Loxo Oncology, Inc. on the live radar map → 📅 $LLY readout calendar (.ics)| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| LIBRETTO-531 NCT04211337 |
P3 | Active, not recruiting | Medullary Thyroid Cancer | 291 | 2023-05-22 (+3 mo) |
| BRUIN CLL-321 NCT04666038 |
P3 | Active, not recruiting | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma | 238 | 2023-08-29 (-4 mo) |
| BRUIN-CLL-313 NCT05023980 |
P3 | Active, not recruiting | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma | 282 | 2025-07-11 (+8 mo) |
| BRUIN CLL-322 NCT04965493 |
P3 | Active, not recruiting | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma | 600 | 2026-10 (+12 mo) |
| BRUIN-CLL-314 NCT05254743 |
P3 | Recruiting | Chronic Lymphocytic Leukemia; Leukemia, Lymphocytic | 737 | 2027-10 (-5 mo) |
| BRUIN-MCL-321 NCT04662255 |
P3 | Active, not recruiting | Lymphoma, Mantle-Cell | 500 | 2027-11 (+39 mo) |
| Pirtobrutinib NCT06588478 |
P2 | Recruiting | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma | 249 | 2028-06 |